An interventional study of Intermittent intrapulmonary deflation in Bronchiectasis and Mucus; Plug, sponsored by Inogen Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Inogen Inc. · Not applicable, Interventional, and Treatment
The purpose of this single arm post-market observational study is to evaluate the short-term effectiveness of the Simeox 200 airway clearance device in improving airway clearance in adult patients aged 18 to 85 with bronchiectasis and chronic mucus hypersecretion. The study aims to establish a baseline for wet sputum weight production using the Simeox 200 device. Additionally, the study aims to assess the short-term effects of Simeox 200 on various outcomes, including lung function, respiratory symptoms, and health-related quality of life.
The study participants will undergo the following steps:
Airway clearance techniques (ACTs) are essential for removing excess bronchial secretions and preventing airway complications. However, their effectiveness relies on patient adherence and satisfaction. Simoex 200 is a novel airway clearance device that uses intermittent negative oscillating pressure to mobilize airway secretions from different parts of the lungs to central airways, facilitating expectoration. Preliminary studies in Europe on patients with chronic muco-obstructive lung diseases have demonstrated the effectiveness and good tolerance of previous generations of the device. This pilot study will evaluate the Simeox 200 device in a home care setting for patients with bronchiectasis and excessive mucus production. The results of this study will inform a future larger-scale clinical trial.
Exclusion Criteria:
Simeox 200 airway clearance device
Device: Intermittent intrapulmonary deflation
Two treatment sessions daily for two weeks
Wet sputum weight collected with Simeox 200 during device training visit
Patients will be instructed during device training visit (V1) to spill all sputum into a pre-weighed pot from at least two supervised sessions. Immediately after collection, all sputum will be weighed on weighing scales with an accuracy of 0.01 grams.
Time frame: From the first training session to the last, and up to one hour following each treatment session the day of training device visit.
Change from baseline in Forced Expiratory Volume in One seconde (FEV1) at the final study visit (V2) after 14 days of treatment
FEV1will be measured with a spirometer according to the ATS guidelines immediately before any procedures at the study site
Time frame: From enrollment to the final study visit at 15 days
Change from baseline in Forced Vital Capacity (FVC) at the final study visit after 14 days of treatment
FVC will be measured with a spirometer according to the ATS guidelines immediately before any procedures at the study site
Time frame: From enrollment to the final study visit at 15 days
Change from baseline in Forced Expiratory Flow between 25% and 75% of vital capacity (FEF25-75%) at the final study visit after 14 days of treatment
FEF25-75% will be measured with a spirometer according to the ATS guidelines immediately before any procedures at the study site
Time frame: From enrollment to the final study visit at 15 days
Change from baseline in Peripheral blood oxygen saturation (SpO2) at final study visit after 14 days of treatment
SpO2 will be measured transcutaneously at rest with a fingertip pulse oximeter before lung function measurements at rest and any procedures with the device at the study site
Time frame: From enrollment to the final study visit at 15 days
Change from baseline in perceived respiratory symptoms assessed with the Breathlessness, Cough and Sputum Scale (BCSS) at 7 and 14 days of treatment
BCSS is a patient-reported outcome measure that asks patients to rate the severity of the three symptoms breathing difficulty, cough, and sputum levels, each on a 5-point scale from 0 (no symptom) to 4 (highest severe symptom)
Time frame: From enrollment to 7 and 14 days of treatment at home
The change from device training visit in wet sputum weight at the final study visit after 14 days of treatment
Patients will be instructed to spill all sputum into a pre-weighed pot. Immediately after collection, all sputum will be weighed on weighing scales with an accuracy of 0.01 grams.
Time frame: From device training visit to the final study visit at 15 days
The change from baseline in airway-disease health status assessed by the Chronic Airway Assessement Test (CAAT) and QOL - B questionnaire at the final study visit after 14 days of treatment
The CAAT is an 8-item questionnaire designed for assessing the impact of a chronic respiratory disease such as bronchiectasis on a person's life. The questionnaire covers symptoms (such as cough, sputum, chest tightness and breathlessness) and disease impacts (including physical activity, confidence, sleep and energy) assessed each on a 6-point scale from 0 (best outcome) to 5 (worst outcome). The QOL-B on the other hand is a self-administered, patient-reported outcome measure assessing symptoms, functioning and health-related quality of life for patients bronchiectasis.
Time frame: From enrollment to the final study visit at 15 days
The change from baseline in walking distance assessed with 6-minutes Walking Test (6MWT) at the final study visit after 14 days of treatment
The 6MWT is a low-intensity, submaximal exercise test used to assess aerobic capacity and endurance and oxygen saturation. 6MWT will be performed after spirometry assessment and in accordance with ATS guidelines. SpO2 will be measured transcutaneously at rest for 5 min before, during and at the end of the 6MWT. A modified Borg scale will be completed beofre and at the end of 6MWT for dyspnea and fatigability scores.
Time frame: From enrollment to the final study visit at 15 days
The change from baseline in borg dyspnea and fatigue score after 6MWT compared to borg dyspnea and fatigue score after 6MWT at the final study visit after 14 days of treatment respectively.
The 6MWT is a low-intensity, submaximal exercise test used to assess aerobic capacity and endurance and oxygen saturation. 6MWT will be performed after spirometry assessment and in accordance with ATS guidelines. SpO2 will be measured transcutaneously at rest for 5 min before, during and at the end of the 6MWT. A modified Borg scale will be completed before and at the end of 6MWT for dyspnea and fatigability scores.
Time frame: From enrollment to the final study visit at 15 days
The global patient satisfaction will be evaluated with Lickert scale at the final study visit after 14 days of treatment
Likert scale measures respondents' level of agreement/satisfaction or disagreement/dissatisfaction towards the treatment on the following attributes: overall / learning time / easy to handle / subjective effectiveness / treatment duration / use in autonomy. These rating scales offer 10 response options, ranging from 0 (worst outcome) to 10 (best outcome).
Time frame: At the final study visit at 15 days
Adherence to the device over the entire period of home use
The patient will record adherence to Simeox 200 on a daily diary at home, noting the number of sessions per day and the duration of each session.
Time frame: From the first day of device use at home to the 14 days of home treatment
Plan to share: Undecided — Plan has not been decided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inogen Inc.